The company has said royalty is 5% to 15% range but Morgans who are the corporate advisor is stating 10% minimum.
Also they are using a test price BASE case of US$150 but I heard it is more likely to be around the US$250 mark.. the test price will become public later this year after more insurers sign up and the price range is put on the US govt website. The larger players will pay a bit less and the smaller insurers will pay a higher price.. this is volume related .
Expect more jurisdictions signed up in the near term and Richard has said they are looking to do some form of large deal for the Endometriosis test where a major global player may take it to market. Expect a much faster path to commercialisation for Endo than for DKD.
Exciting times.
PIQ Price at posting:
$1.03 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)